Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology

Small cell lung cancer (SCLC) is an aggressive neuroendocrine disease with an overall 5 year survival rate of ~7%. Although patients tend to respond initially to therapy, therapy-resistant disease inevitably emerges. Unfortunately, there are no validated biomarkers for early-stage SCLC to aid in ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Mambetsariev, Isa, Mirzapoiazova, Tamara, Lennon, Frances, Jolly, Mohit Kumar, Li, Haiqing, Nasser, Mohd W., Vora, Lalit, Kulkarni, Prakash, Batra, Surinder K., Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679065/
https://www.ncbi.nlm.nih.gov/pubmed/31315252
http://dx.doi.org/10.3390/jcm8071038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679065/
https://www.ncbi.nlm.nih.gov/pubmed/31315252
http://dx.doi.org/10.3390/jcm8071038

Ejemplares similares